Tenaya Therapeutics (TNYA)
(Delayed Data from NSDQ)
$2.72 USD
+0.07 (2.64%)
Updated Aug 12, 2024 04:00 PM ET
After-Market: $2.73 +0.01 (0.37%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Balance Sheet
Fiscal Year End for Tenaya Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 105 | 187 | 251 | 129 | 27 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 7 | 7 | 4 | 1 | 1 |
Total Current Assets | 112 | 194 | 255 | 130 | 28 |
Net Property & Equipment | 43 | 51 | 43 | 17 | 10 |
Investments & Advances | 0 | 18 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 6 | 5 | 4 | 1 | 1 |
Total Assets | 171 | 279 | 314 | 148 | 38 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 10 | 11 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 13 | 11 | 9 | 3 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 1 | 2 |
Total Current Liabilities | 23 | 24 | 22 | 5 | 4 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 4 | 5 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 31 | 36 | 36 | 9 | 9 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 221 | 73 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 543 | 523 | 434 | 2 | 1 |
Retained Earnings | -403 | -279 | -156 | -83 | -44 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 139 | 243 | 279 | 139 | -44 |
Total Liabilities & Shareholder's Equity | 171 | 279 | 314 | 148 | 38 |
Total Common Equity | 139 | 243 | 279 | -81 | -117 |
Shares Outstanding | 68.10 | 66.80 | 41.20 | NA | NA |
Book Value Per Share | 2.05 | 3.64 | 6.76 | 0.00 | 0.00 |
Fiscal Year End for Tenaya Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 99 | 122 | 105 | 122 | 133 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 6 | 7 | 5 | 6 |
Total Current Assets | 105 | 129 | 112 | 127 | 139 |
Net Property & Equipment | 39 | 41 | 43 | 45 | 47 |
Investments & Advances | 0 | 0 | 0 | 6 | 19 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 5 | 6 | 6 | 6 | 6 |
Total Assets | 163 | 185 | 171 | 193 | 221 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 7 | 6 | 6 | 8 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 9 | 8 | 13 | 10 | 9 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 17 | 19 | 23 | 19 | 21 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 29 | 27 | 31 | 29 | 31 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 599 | 594 | 543 | 538 | 534 |
Retained Earnings | -465 | -436 | -403 | -373 | -344 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 134 | 158 | 139 | 165 | 190 |
Total Liabilities & Shareholder's Equity | 163 | 185 | 171 | 193 | 221 |
Total Common Equity | 134 | 158 | 139 | 165 | 190 |
Shares Outstanding | 78.50 | 78.50 | 68.10 | 67.80 | 66.80 |
Book Value Per Share | 1.71 | 2.02 | 2.05 | 2.43 | 2.84 |